Biopharmaceuticals Top Open Access Journals
Biopharmaceuticals are clinical medications delivered utilizing biotechnology. They are proteins including antibodies, nucleic acids utilized for restorative or in vivo analytic purposes, and are created by implies other than direct extraction from a local (non-built) organic source. A biopharmaceutical, otherwise called a biologic clinical item, or biologic, is any pharmaceutical medication item fabricated in, separated from, or semisynthesized from organic sources. Not the same as completely incorporated pharmaceuticals, they incorporate immunizations, blood, blood parts, allergenics, substantial cells, quality treatments, tissues, recombinant remedial protein, and living prescriptions utilized in cell treatment. Biologics can be made out of sugars, proteins, or nucleic acids or complex blends of these substances, or might be living cells or tissues. They are disconnected from living sources human, creature, plant, parasitic, or microbial.
Terminology encompassing biopharmaceuticals shifts among gatherings and substances, with various terms alluding to various subsets of therapeutics inside the general biopharmaceutical class. Some administrative organizations utilize the terms natural restorative items or helpful natural item to allude explicitly to designed macromolecular items like protein-and nucleic corrosive based medications, recognizing them from items like blood, blood segments, or antibodies, which are typically removed straightforwardly from an organic source.
High Impact List of Articles
-
Current Research in Pharmacovigilance and Bio-Pharmaceutical Science, December 02-03, Auckland, Newzeland
Dr. Vahideh Nasr Market Analysis: Pharmaceutical Regulatory Affairs: Open Access
-
Current Research in Pharmacovigilance and Bio-Pharmaceutical Science, December 02-03, Auckland, Newzeland
Dr. Vahideh Nasr Market Analysis: Pharmaceutical Regulatory Affairs: Open Access
-
Emergence in the Lipid-Based Nanostructured Systems for Optimizing Oral Delivery of Drugs
Swain S and Beg S Editorial: Pharmaceutical Regulatory Affairs: Open Access
-
Emergence in the Lipid-Based Nanostructured Systems for Optimizing Oral Delivery of Drugs
Swain S and Beg S Editorial: Pharmaceutical Regulatory Affairs: Open Access
-
The Retail Pharmacy Market in the Brazilian Federal District
Silva Naves J, Fiolle AD, Lustosa FLF, Godinho MGP and Filho JBO Research Article: Pharmaceutical Regulatory Affairs: Open Access
-
The Retail Pharmacy Market in the Brazilian Federal District
Silva Naves J, Fiolle AD, Lustosa FLF, Godinho MGP and Filho JBO Research Article: Pharmaceutical Regulatory Affairs: Open Access
-
Therapeutic Opportunities through the Modulation of Endocannabinoid Transport
Jason J Guo, Mark K Williams and Alexandros Makriyannis Editorial: Pharmaceutical Regulatory Affairs: Open Access
-
Therapeutic Opportunities through the Modulation of Endocannabinoid Transport
Jason J Guo, Mark K Williams and Alexandros Makriyannis Editorial: Pharmaceutical Regulatory Affairs: Open Access
-
Journal of Pharmaceutical Regulatory Affairs: Filling the Gap between Science and Usability
Helmut Niederhofer Editorial: Pharmaceutical Regulatory Affairs: Open Access
-
Journal of Pharmaceutical Regulatory Affairs: Filling the Gap between Science and Usability
Helmut Niederhofer Editorial: Pharmaceutical Regulatory Affairs: Open Access
Conference Proceedings
-
Microalgae biofuel commercialization challenges
Armen B Avagyan Posters & Accepted Abstracts: Journal of Bioprocessing & Biotechniques
-
Microalgae biofuel commercialization challenges
Armen B Avagyan Posters & Accepted Abstracts: Journal of Bioprocessing & Biotechniques
-
Bioequivalence of Salmeterol xinafoate/Fluticasone propionate HFA pMDI of two different strengths (25/250 mcg and 25/125 mcg per actuation) in healthy volunteers
Muneesh Garg, Raghu Naidu, Amolkumar Birhade, Krishnan Iyer1, Ratnakar Jadhav
Juliet Rebello, Nazma Morde, Mayuri Mangale and Bill Brashier Scientific Tracks Abstracts: Journal of Bioanalysis & Biomedicine
-
Bioequivalence of Salmeterol xinafoate/Fluticasone propionate HFA pMDI of two different strengths (25/250 mcg and 25/125 mcg per actuation) in healthy volunteers
Muneesh Garg, Raghu Naidu, Amolkumar Birhade, Krishnan Iyer1, Ratnakar Jadhav
Juliet Rebello, Nazma Morde, Mayuri Mangale and Bill Brashier Scientific Tracks Abstracts: Journal of Bioanalysis & Biomedicine
-
Evolving biosimilars regulatory landscape: US and EU
Kamali Chance Keynote: Journal of Bioanalysis & Biomedicine
-
Evolving biosimilars regulatory landscape: US and EU
Kamali Chance Keynote: Journal of Bioanalysis & Biomedicine
-
Changing landscape of healthcare, regulations and role of RA
Rama K. Pidaparti Keynote: Pharmaceutical Regulatory Affairs: Open Access
-
Changing landscape of healthcare, regulations and role of RA
Rama K. Pidaparti Keynote: Pharmaceutical Regulatory Affairs: Open Access
-
Micellar Solubilization in the formulation development of poorly soluble Naproxen
P. Durga Maheswari, D. Rambhau., M. Laxmi Narasu and Mitrabhanu Mohanty Posters: Pharmaceutical Regulatory Affairs: Open Access
-
Micellar Solubilization in the formulation development of poorly soluble Naproxen
P. Durga Maheswari, D. Rambhau., M. Laxmi Narasu and Mitrabhanu Mohanty Posters: Pharmaceutical Regulatory Affairs: Open Access
Relevant Topics in Pharmaceutical Sciences